Mucosal gene signatures to predict response to infliximab in patients with inflammatory bowel disease

被引：0
|
作者：
Arijs, Ingrid
Van Lommel, Leentje
Van Steen, Kristel
De Hertogh, Gert
Ferrante, Marc
Joossens, Marie
Geboes, Karel
Van Assche, Gen A.
Vermeire, Severine
Schuit, Frans C.
Rutgeerts, Paul J.
机构：
来源：
GASTROENTEROLOGY | 2008年 / 134卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A117 / A117
页数：1
相关论文
共 50 条
  • [1] Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis
    Arijs, I.
    Li, K.
    Toedter, G.
    Quintens, R.
    Van Lommel, L.
    Van Steen, K.
    Leemans, P.
    De Hertogh, G.
    Lemaire, K.
    Ferrante, M.
    Schnitzler, F.
    Thorrez, L.
    Ma, K.
    Song, X. -Y R.
    Marano, C.
    Van Assche, G.
    Vermeire, S.
    Geboes, K.
    Schuit, F.
    Baribaud, F.
    Rutgeerts, P.
    GUT, 2009, 58 (12) : 1612 - 1619
  • [2] Can Mucosal Gene Signatures predict Response to Infliximab in Patients with refractory Ulcerative Colitis?
    Schmitz, F.
    GASTROENTEROLOGE, 2010, 5 (01): : 52 - 53
  • [3] Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease
    Pariente, Benjamin
    de Chambrun, Guillaume Pineton
    Krzysiek, Roman
    Desroches, Marine
    Louis, Gauthier
    De Cassan, Chiara
    Baudry, Clotilde
    Gornet, Jean-Marc
    Desreumaux, Pierre
    Emilie, Dominique
    Colombel, Jean-Frederic
    Allez, Matthieu
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (07) : 1199 - 1206
  • [4] Primary Non Response to Infliximab in Patients With Inflammatory Bowel Disease
    Papamichael, Konstantinos
    Gazouli, Maria
    Tsirogianni, Alexandra
    Archavlis, Emmanuel J.
    Christidou, Angeliki
    Kyriakos, Nikolaos
    Karatzas, Pantelis
    Papasteriadi, Chryssa
    Mantzaris, Gerassimos J.
    GASTROENTEROLOGY, 2014, 146 (05) : S457 - S457
  • [5] Megacolon in inflammatory bowel disease: response to infliximab
    Nunez-Ortiz, Andrea
    Trigo-Salado, Claudio
    Dolores de la Cruz-Ramirez, Maria
    Luis Marquez-Galan, Jose
    Manuel Herrera-Justiniano, Jose
    Leo-Carnerero, Eduardo
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2020, 112 (02) : 90 - 93
  • [6] Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease
    Curci, Debora
    Lucafo, Marianna
    Cifu, Adriana
    Fabris, Martina
    Bramuzzo, Matteo
    Martelossi, Stefano
    Franca, Raffaella
    Decorti, Giuliana
    Stocco, Gabriele
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (06): : 2184 - 2192
  • [7] The Impact of Infliximab Therapy on Intestinal Mucosal Gene Expression of Endothelial Cell Adhesion Molecules in Patients With Inflammatory Bowel Disease
    Arijs, Ingrid
    Quintens, Roel
    Lemaire, Katleen
    Van Lommel, Leentje
    Van Steen, Kristel
    De Hertogh, Gert
    Van Assche, Gert A.
    Vermeire, Severine
    Geboes, Karel
    Schuit, Frans C.
    Rutgeerts, Paul J.
    GASTROENTEROLOGY, 2010, 138 (05) : S677 - S677
  • [8] Mucosal Microbiota Composition Predicts Infliximab Response in Inflammatory Bowel Diseases
    Gazouli, M.
    Dovrolis, N.
    Kolios, G.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I196 - I196
  • [9] Infliximab pharmacokinetics in inflammatory Bowel disease patients
    Ternant, David
    Aubourg, Alexandre
    Magdelaine-Beuzelin, Charlotte
    Degenne, Danielle
    Watier, Herve
    Picon, Laurence
    Paintaud, Gilles
    THERAPEUTIC DRUG MONITORING, 2008, 30 (04) : 523 - 529
  • [10] Gut mucosal microbiota composition in Inflammatory Bowel Disease introduced to infliximab
    Ventin-Holmberg, R.
    Lindholm, J.
    Eberl, A.
    Taina, S.
    Saavalainen, P.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 1036 - 1036
12345